Cue biopharma announces upcoming scientific presentations at the society for immunotherapy of cancer's (sitc) 38th annual meeting

Boston, sept. 27, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, announced today two poster presentations highlighting the company's immuno-stat™ platform and lead clinical assets cue-101 and cue-102, representative of the cue-100 series, at the society for immunotherapy of cancer's 38th anniversary annual meeting (sitc 2023). the conference will be held in san diego, california and virtually on november 1-5, 2023.
CUE Ratings Summary
CUE Quant Ranking